173 related articles for article (PubMed ID: 11516780)
1. Cytokines as adjuvants for the induction of mucosal immunity.
Boyaka PN; McGhee JR
Adv Drug Deliv Rev; 2001 Sep; 51(1-3):71-9. PubMed ID: 11516780
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.
Boyaka PN; Tafaro A; Fischer R; Fujihashi K; Jirillo E; McGhee JR
Curr Pharm Des; 2003; 9(24):1965-72. PubMed ID: 12871182
[TBL] [Abstract][Full Text] [Related]
4. Lymphotactin acts as an innate mucosal adjuvant.
Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR
J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.
Bielinska AU; O'Konek JJ; Janczak KW; Baker JR
Vaccine; 2016 Jul; 34(34):4017-24. PubMed ID: 27317451
[TBL] [Abstract][Full Text] [Related]
6. IL-12 is an effective adjuvant for induction of mucosal immunity.
Boyaka PN; Marinaro M; Jackson RJ; Menon S; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):122-8. PubMed ID: 9886377
[TBL] [Abstract][Full Text] [Related]
7. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
8. RANTES potentiates antigen-specific mucosal immune responses.
Lillard JW; Boyaka PN; Taub DD; McGhee JR
J Immunol; 2001 Jan; 166(1):162-9. PubMed ID: 11123289
[TBL] [Abstract][Full Text] [Related]
9. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.
Ebensen T; Libanova R; Schulze K; Yevsa T; Morr M; Guzmán CA
Vaccine; 2011 Jul; 29(32):5210-20. PubMed ID: 21619907
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H
J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076
[TBL] [Abstract][Full Text] [Related]
11. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
[TBL] [Abstract][Full Text] [Related]
12. Nasal immunization with the 40-kDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice.
Cai Y; Kurita-Ochiai T; Kobayashi R; Hashizume T; Yamamoto M
J Oral Sci; 2013; 55(2):107-14. PubMed ID: 23748449
[TBL] [Abstract][Full Text] [Related]
13. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins.
Lillard JW; Boyaka PN; Chertov O; Oppenheim JJ; McGhee JR
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):651-6. PubMed ID: 9892688
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
16. [Nasal vaccines].
Kido H; Mizuno D; Takei T
Nihon Rinsho; 2008 Oct; 66(10):1881-7. PubMed ID: 18939485
[TBL] [Abstract][Full Text] [Related]
17. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
[TBL] [Abstract][Full Text] [Related]
18. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity.
Boyaka PN; Marinaro M; Jackson RJ; van Ginkel FW; Cormet-Boyaka E; Kirk KL; Kensil CR; McGhee JR
J Immunol; 2001 Feb; 166(4):2283-90. PubMed ID: 11160283
[TBL] [Abstract][Full Text] [Related]
19. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively.
Hiroi T; Iwatani K; Iijima H; Kodama S; Yanagita M; Kiyono H
Eur J Immunol; 1998 Oct; 28(10):3346-53. PubMed ID: 9808204
[TBL] [Abstract][Full Text] [Related]
20. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
